Related Experiment Video
Updated: Feb 8, 2026
09:00
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
16.3K
Hyperbaric Oxygenationt for Ulcerative Graft-Versus-Host Disease: A Case Report
1Denise M. Weiss.
Clinical Journal of Oncology Nursing
|February 6, 2026
Summary
Acute myeloid leukemia (AML) is an aggressive blood cancer originating from stem cell mutations. Allogeneic hematopoietic stem cell transplantation offers a potentially curative treatment option for AML patients.
Area of Science:
- Hematology
- Oncology
- Stem Cell Biology
Background:
- Acute myeloid leukemia (AML) is a serious blood cancer characterized by uncontrolled proliferation of myeloid blasts.
- AML arises from genetic and epigenetic alterations in hematopoietic stem cells, leading to malignant transformation.
- The aggressive nature of AML necessitates intensive treatment strategies.
Purpose of the Study:
- To review the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in managing AML.
- To discuss the potential curative aspects of allo-HSCT for AML.
- To highlight the complexities and intensive management required for AML patients.
Main Methods:
- Literature review of studies on AML pathogenesis and treatment.
- Analysis of clinical outcomes data for AML patients undergoing allo-HSCT.
- Synthesis of current knowledge on stem cell biology in AML.
Main Results:
- Allogeneic hematopoietic stem cell transplantation is a potentially curative therapeutic option for select AML patients.
- Intensive management is crucial for successful outcomes in AML treatment.
- Stem cell changes are the underlying cause of AML development.
Conclusions:
- Allo-HSCT represents a significant treatment modality for AML, offering a chance for cure.
- Effective AML management requires a multidisciplinary approach and intensive therapeutic interventions.
- Further research into stem cell biology may reveal novel therapeutic targets for AML.
More Related Videos
Related Concept Videos
01:28Peptic Ulcer Disease II: Pathophysiology
2.1K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.1K
01:30Peptic Ulcer Disease I: Introduction
856
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
856
01:26Peptic Ulcer Disease IV: Management
521
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
521
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
1.0K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.0K
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.2K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.2K
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.3K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.3K